Abstract
Introduction: The St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 recognized substantial progress in the pathological characterization of breast cancer subtypes. A useful surrogate definition was developed to distinguish luminal A-like breast cancer from luminal B-like disease based on a combination of estrogen receptor (ER), progesterone receptor (PgR) and Ki-67 status, without a requirement for molecular diagnostics. Differences depend upon the choice of the threshold value for Ki-67 and the requirement for substantial PgR positivity. We aimed to verify the suitability of the new surrogate definitions of luminal subtypes in terms of distant disease control in a large series of patients.Methods: We studied 9,415 women with a median follow-up of 8.1 years who (1) had ER-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer and (2) had undergone surgery at the European Institute of Oncology between 1994 and 2006. We evaluated distant disease-free survival of patients with " low" (
| Original language | English |
|---|---|
| Article number | R65 |
| Journal | Breast Cancer Research |
| Volume | 16 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - Jun 20 2014 |
Fingerprint
ASJC Scopus subject areas
- Cancer Research
- Oncology
- Medicine(all)
Cite this
Proposed new clinicopathological surrogate definitions of luminal A and luminal B (HER2-negative) intrinsic breast cancer subtypes. / Maisonneuve, Patrick; Disalvatore, Davide; Rotmensz, Nicole; Curigliano, Giuseppe; Colleoni, Marco; Dellapasqua, Silvia; Pruneri, Giancarlo; Mastropasqua, Mauro G.; Luini, Alberto; Bassi, Fabio; Pagani, Gianmatteo; Viale, Giuseppe; Goldhirsch, Aron.
In: Breast Cancer Research, Vol. 16, No. 3, R65, 20.06.2014.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Proposed new clinicopathological surrogate definitions of luminal A and luminal B (HER2-negative) intrinsic breast cancer subtypes
AU - Maisonneuve, Patrick
AU - Disalvatore, Davide
AU - Rotmensz, Nicole
AU - Curigliano, Giuseppe
AU - Colleoni, Marco
AU - Dellapasqua, Silvia
AU - Pruneri, Giancarlo
AU - Mastropasqua, Mauro G.
AU - Luini, Alberto
AU - Bassi, Fabio
AU - Pagani, Gianmatteo
AU - Viale, Giuseppe
AU - Goldhirsch, Aron
PY - 2014/6/20
Y1 - 2014/6/20
N2 - Introduction: The St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 recognized substantial progress in the pathological characterization of breast cancer subtypes. A useful surrogate definition was developed to distinguish luminal A-like breast cancer from luminal B-like disease based on a combination of estrogen receptor (ER), progesterone receptor (PgR) and Ki-67 status, without a requirement for molecular diagnostics. Differences depend upon the choice of the threshold value for Ki-67 and the requirement for substantial PgR positivity. We aimed to verify the suitability of the new surrogate definitions of luminal subtypes in terms of distant disease control in a large series of patients.Methods: We studied 9,415 women with a median follow-up of 8.1 years who (1) had ER-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer and (2) had undergone surgery at the European Institute of Oncology between 1994 and 2006. We evaluated distant disease-free survival of patients with " low" (
AB - Introduction: The St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 recognized substantial progress in the pathological characterization of breast cancer subtypes. A useful surrogate definition was developed to distinguish luminal A-like breast cancer from luminal B-like disease based on a combination of estrogen receptor (ER), progesterone receptor (PgR) and Ki-67 status, without a requirement for molecular diagnostics. Differences depend upon the choice of the threshold value for Ki-67 and the requirement for substantial PgR positivity. We aimed to verify the suitability of the new surrogate definitions of luminal subtypes in terms of distant disease control in a large series of patients.Methods: We studied 9,415 women with a median follow-up of 8.1 years who (1) had ER-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer and (2) had undergone surgery at the European Institute of Oncology between 1994 and 2006. We evaluated distant disease-free survival of patients with " low" (
UR - http://www.scopus.com/inward/record.url?scp=84904045535&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84904045535&partnerID=8YFLogxK
U2 - 10.1186/bcr3679
DO - 10.1186/bcr3679
M3 - Article
VL - 16
JO - Breast Cancer Research
JF - Breast Cancer Research
SN - 1465-5411
IS - 3
M1 - R65
ER -